Comparing of Brainstorm Cell Therapeutics Inc. (BCLI) and Cara Therapeutics Inc. (NASDAQ:CARA) – The Broch Herald

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Cara Therapeutics Inc. (NASDAQ:CARA) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Valuation & Earnings

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 provides us the net margins, return on assets and return on equity of both businesses.

Risk & Volatility

Brainstorm Cell Therapeutics Inc. has a 1.37 beta, while its volatility is 37.00% which is more volatile than Standard and Poors 500. Cara Therapeutics Inc. has a 2.4 beta and it is 140.00% more volatile than Standard and Poors 500.

Liquidity

Brainstorm Cell Therapeutics Inc.s Current Ratio and Quick Ratio are 0.4 and 0.4 respectively. The Current Ratio and Quick Ratio of its competitor Cara Therapeutics Inc. are 4.2 and 4.2 respectively. Cara Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Brainstorm Cell Therapeutics Inc.

Analyst Ratings

Brainstorm Cell Therapeutics Inc. and Cara Therapeutics Inc. Ratings and Recommendations are available in the next table.

Brainstorm Cell Therapeutics Inc.s upside potential currently stands at 133.77% and an $9 average target price. Meanwhile, Cara Therapeutics Inc.s average target price is $35.67, while its potential upside is 115.27%. The information presented earlier suggests that Brainstorm Cell Therapeutics Inc. looks more robust than Cara Therapeutics Inc. as far as analyst opinion.

Institutional and Insider Ownership

Brainstorm Cell Therapeutics Inc. and Cara Therapeutics Inc. has shares owned by institutional investors as follows: 9.5% and 66.7%. Insiders owned roughly 10.4% of Brainstorm Cell Therapeutics Inc.s shares. Insiders Competitively, owned 2.2% of Cara Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc. was less bullish than Cara Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The companys lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More here:
Comparing of Brainstorm Cell Therapeutics Inc. (BCLI) and Cara Therapeutics Inc. (NASDAQ:CARA) - The Broch Herald